Axl Gene Knockdown Inhibits the Metastasis Properties of Hepatocellular Carcinoma Via PI3K/Akt-PAK1 Signal Pathway

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2013 Dec 19

PMID 24347489

Citations 21

Authors

JingChao Xu

Li Jia

Hongye Ma

Yanping Li

Zhenhai Ma

Yongfu Zhao

Affiliations

Soon will be listed here.

Abstract

The objective of this study is to clarify the possible role and mechanism of Axl in the tumorigenicity and metastasis process of hepatocellular carcinoma. The mRNA and protein expression levels of Axl in MHCC97-H and MHCC97-L cell lines were evaluated by real-time PCR and Western blot analysis. The key factor of phosphatidylinositol-3-kinase (PI3K)/Akt-p21-activated kinases-1 (PAK1) signaling pathway was studied after Axl expression was downregulated by shRNA. Finally, we analyzed the expression status of Axl protein expression in hepatocellular carcinoma tissues and its relationship with the prognosis of hepatocellular carcinoma. Axl was observed to be higher expressed in MHCC97-H cell lines compared to MHCC97-L cell lines. The downregulation of Axl in MHCC97-H cell lines resulted in the inhibition of the invasion ability of MHCC97-H cells both in vitro and in vivo. Interestingly, blocking PI3K/Akt signaling pathway by LY294002 or Akt siRNA could remarkably inhibit the PAK1 activation and cell invasion. Finally, the Axl protein expression was positively correlated with differentiation, lymph node metastasis, and clinical stage in patients with hepatocellular carcinoma patients (all P < 0.01). These findings suggest that Axl can also regulate the metastasis process of hepatocellular carcinoma and may serve as a new prognostic marker and therapeutic target for treating hepatocellular carcinoma metastasis.

Citing Articles

From MASH to HCC: the role of Gas6/TAM receptors.

Apostolo D, Ferreira L, Vincenzi F, Vercellino N, Minisini R, Latini F Front Immunol. 2024; 15:1332818.

PMID: 38298195 PMC: 10827955. DOI: 10.3389/fimmu.2024.1332818.

Structure-based drug discovery of novel fused-pyrazolone carboxamide derivatives as potent and selective AXL inhibitors.

Fang F, Dai Y, Wang H, Ji Y, Liang X, Peng X Acta Pharm Sin B. 2023; 13(12):4918-4933.

PMID: 38045061 PMC: 10692477. DOI: 10.1016/j.apsb.2023.10.002.

The Characterization and Differential Analysis of mA Methylation in Hycole Rabbit Muscle and Adipose Tissue and Prediction of Regulatory Mechanism about Intramuscular Fat.

Luo G, Ai Y, Yu L, Wang S, Ren Z Animals (Basel). 2023; 13(3).

PMID: 36766336 PMC: 9913852. DOI: 10.3390/ani13030446.

AXL and MET in Hepatocellular Carcinoma: A Systematic Literature Review.

Hsu C, Huang Y, Lin S, Hsu C Liver Cancer. 2022; 11(2):94-112.

PMID: 35634427 PMC: 9109073. DOI: 10.1159/000520501.

AXL Knock-Out in SNU475 Hepatocellular Carcinoma Cells Provides Evidence for Lethal Effect Associated with G2 Arrest and Polyploidization.

Batur T, Argundogan A, Keles U, Mutlu Z, Alotaibi H, Senturk S Int J Mol Sci. 2021; 22(24).

PMID: 34948046 PMC: 8708332. DOI: 10.3390/ijms222413247.

References

Li J, Jia L, Ma Z, Ma Q, Yang X, Zhao Y . Axl glycosylation mediates tumor cell proliferation, invasion and lymphatic metastasis in murine hepatocellular carcinoma. World J Gastroenterol. 2012; 18(38):5369-76. PMC: 3471105. DOI: 10.3748/wjg.v18.i38.5369. View

Tian J, Tang Z, Ye S, Liu Y, Lin Z, Chen J . New human hepatocellular carcinoma (HCC) cell line with highly metastatic potential (MHCC97) and its expressions of the factors associated with metastasis. Br J Cancer. 1999; 81(5):814-21. PMC: 2374300. DOI: 10.1038/sj.bjc.6690769. View

Linger R, Keating A, Earp H, Graham D . TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res. 2008; 100:35-83. PMC: 3133732. DOI: 10.1016/S0065-230X(08)00002-X. View

Vajkoczy P, Knyazev P, Kunkel A, Capelle H, Behrndt S, von Tengg-Kobligk H . Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. Proc Natl Acad Sci U S A. 2006; 103(15):5799-804. PMC: 1458653. DOI: 10.1073/pnas.0510923103. View

Gschwind A, Fischer O, Ullrich A . The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer. 2004; 4(5):361-70. DOI: 10.1038/nrc1360. View

Nemoto T, Ohashi K, Akashi T, Johnson J, Hirokawa K . Overexpression of protein tyrosine kinases in human esophageal cancer. Pathobiology. 1997; 65(4):195-203. DOI: 10.1159/000164123. View

Christofori G . New signals from the invasive front. Nature. 2006; 441(7092):444-50. DOI: 10.1038/nature04872. View

Schutte K, Bornschein J, Malfertheiner P . Hepatocellular carcinoma--epidemiological trends and risk factors. Dig Dis. 2009; 27(2):80-92. DOI: 10.1159/000218339. View

Papakonstanti E, Stournaras C . Association of PI-3 kinase with PAK1 leads to actin phosphorylation and cytoskeletal reorganization. Mol Biol Cell. 2002; 13(8):2946-62. PMC: 117954. DOI: 10.1091/mbc.02-01-0599. View

10.

Cinti C, Vindigni C, Zamparelli A, La Sala D, Epistolato M, Marrelli D . Activated Akt as an indicator of prognosis in gastric cancer. Virchows Arch. 2008; 453(5):449-55. DOI: 10.1007/s00428-008-0676-8. View

11.

Hafizi S, Dahlback B . Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases. Cytokine Growth Factor Rev. 2006; 17(4):295-304. DOI: 10.1016/j.cytogfr.2006.04.004. View

12.

Stitt T, Conn G, Goret M, Lai C, Bruno J, Radzlejewski C . The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell. 1995; 80(4):661-670. DOI: 10.1016/0092-8674(95)90520-0. View

13.

Tomita Y, Morooka T, Hoshida Y, Zhang B, Qiu Y, Nakamichi I . Prognostic significance of activated AKT expression in soft-tissue sarcoma. Clin Cancer Res. 2006; 12(10):3070-7. DOI: 10.1158/1078-0432.CCR-05-1732. View

14.

Park S, Kim S . Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression. Oncol Rep. 2007; 18(1):139-43. View

15.

Craven R, Xu L, Weiner T, Fridell Y, Dent G, Srivastava S . Receptor tyrosine kinases expressed in metastatic colon cancer. Int J Cancer. 1995; 60(6):791-7. DOI: 10.1002/ijc.2910600611. View

16.

He L, Zhang J, Jiang L, Jin C, Zhao Y, Yang G . Differential expression of Axl in hepatocellular carcinoma and correlation with tumor lymphatic metastasis. Mol Carcinog. 2010; 49(10):882-91. DOI: 10.1002/mc.20664. View

17.

Tai K, Shieh Y, Lee C, Shiah S, Wu C . Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-kappaB and Brg-1. Oncogene. 2008; 27(29):4044-55. DOI: 10.1038/onc.2008.57. View

18.

Sun W, Fujimoto J, Tamaya T . Coexpression of Gas6/Axl in human ovarian cancers. Oncology. 2004; 66(6):450-7. DOI: 10.1159/000079499. View

19.

Ito M, Nakashima M, Nakayama T, Ohtsuru A, Nagayama Y, Takamura N . Expression of receptor-type tyrosine kinase, Axl, and its ligand, Gas6, in pediatric thyroid carcinomas around chernobyl. Thyroid. 2002; 12(11):971-5. DOI: 10.1089/105072502320908303. View

20.

Zantek N, Walker-Daniels J, Stewart J, Hansen R, Robinson D, Miao H . MCF-10A-NeoST: a new cell system for studying cell-ECM and cell-cell interactions in breast cancer. Clin Cancer Res. 2001; 7(11):3640-8. View